FindTrial
Sign In

Effects of 5-HT2A and CYP3A4 Gene Polymorphisms and their interactions on pain perception and opioid dosage in Patients with Lung Cancer

Effects of 5-HT2A and CYP3A4 Gene Polymorphisms and their interactions on pain perception and opioid dosage in Patients with Lung Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800017063
Enrollment
Unknown
Registered
2018-07-10
Start date
2018-06-28
Completion date
Unknown
Last updated
2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

Case series:Nil

Sponsors

Affiliated Hospital of Xuzhou Medical University, Jiangsu Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed as malignant tumors by pathology or cytology; 2. Aged 18 to 80 years old male and female; 3. Without communication obstacle and does not affect assessment.

Exclusion criteria

Exclusion criteria: 1. Suffering from central nervous system diseases or mental diseases; 2. Sudden deterioration of the condition; 3. Those suffering from severe cardiovascular and cerebrovascular diseases; 4. Those who are experiencing other acute diseases; 5. Those who cannot self-evaluate; 6. Before entering the election 3 months to participate in other drug trials.

Design outcomes

Primary

MeasureTime frame
5-HT2A receptor and CYP3A4 gene polymorphisms;Pain perception;Consumption of opioid drug;—

Contacts

Public ContactShen Wen

Affiliated Hospital of Xuzhou Medical University

shenwen1598@sina.com+86 13815311266

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026